EDAP Reports Three New RPP Sites in New German Regions
July 23 2007 - 10:29AM
PR Newswire (US)
PR Marketing & Education Programs to Expand LYON, France, July
23 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), the
global leader in High Intensity Focused Ultrasound (HIFU) treatment
of prostate cancer, continues to penetrate the German HIFU market.
Recent activities including the company's successful HIFU tour and
regional congress presence continue to sign the largest regional
centers as Ablatherm-HIFU users. The company's marketing and
education programs are increasing center traffic with patients
inquiring about HIFU therapy. EDAP sees a growing patient
population being treated in most German HIFU centers in the first
half of 2007 compared to 2006, primarily driven by the aggressive
and effective patient outreach with EDAP's public relations company
in Hamburg. Results include two press conferences, a TV show and
more than 30 articles on Ablatherm-HIFU in the German public press
reaching a readership of 32 million. The PR campaign increased
visits on the German HIFU Planet Website over 400% in the course of
10 months. Judith Johannsen, Director of EDAP GmbH in Germany,
commented, "Due to educational programs, like regular HIFU Tours
organized in hospitals and 10 publications about HIFU in German
medical press like German Urology and Oncology Journals in the last
12 months we face an increasing interest from urologists in
hospitals in HIFU therapy with Ablatherm." EDAP recently signed
three new mobile Revenue Per Procedure (RPP) contracts with large
clinics and hospitals, mainly prostate cancer populations in
regions where HIFU has not been locally available to date. EDAP
signed Hanseklinikum Stralsund GmbH under the direction of Dr.
Bernhard Heider as a mobile RPP site. The first HIFU center in the
area, Stralsund is a large Urology center in northeast Germany near
the Baltic Sea. Dr. Heider successfully performed the first HIFU
treatments in early July. EDAP and Hanseklinikum Stralsund also
conducted a HIFU Tour workshop that day where referring doctors
heard about the long-term experience with Ablatherm HIFU from Dr.
Pfeiffer from Asklepios Klinikum in Hamburg. Ablatherm services
will also begin this summer at Robert-Koch-Krankenhaus Gehrden,
part of the group "Region Hannover GmbH," under the direction of
Dr. Schick and Dr. Schedl. Hannover is in the heart of Germany, and
the hospital is the first HIFU user in this area. The decision to
launch was accelerated because of the successful HIFU Symposium
hosted during the North German congress last April in Hannover. Dr.
Schedl commented: "We will introduce HIFU with Ablatherm to
complete our portfolio for the treatment of prostate cancer,
primarily for the treatment of localized indications and as a
salvage therapy for residual cancer. Ablatherm is a minimally
invasive solution with high benefits for patients. It offers a
curative option for specific individuals under established
indications and needs." Ablatherm-HIFU treatments will also begin
this summer at Klinikum Kempten-Oberallgaeu under direction of Dr.
Gumpinger and Dr. Bayer. This is a huge urology department situated
in the south of Germany, not far from Lake Constance. This is again
the first HIFU center in the region. Johannsen commented: "We are
definitely expanding our HIFU business in Germany. With these three
new RPP contracts, EDAP introduced Ablatherm-HIFU in regions that
were not offering this option to patients with prostate cancer. Our
motivated sales force is doing a great job and strongly focused on
providing each region of Germany with accessibility to this therapy
for patients seeking solutions that will maintain quality of life."
"We are very pleased to see that our newly recruited senior
experienced sales team is delivering and is being successful in
opening new Ablatherm-HIFU centers in Germany," said Marc
Oczachowski, CEO of EDAP. "Our dedicated efforts in marketing and
education programs are being rewarded as we see an increase in
patient traffic at sites offering Ablatherm-HIFU in Germany. We
look forward to continued success in the largest market in Europe
for prostate cancer." About EDAP TMS S.A. EDAP TMS S.A. develops
and markets Ablatherm, the most advanced and clinically proven
choice for High Intensity Focused Ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a
minimally invasive and effective treatment option with a low
occurrence of side effects. Ablatherm-HIFU is generally recommended
for patients with localized prostate cancer (stages T1-T2) who are
not candidates for surgery or who prefer an alternative option, or
for patients who failed radiotherapy treatment. The company is also
developing this technology for the potential treatment of certain
other types of tumors. EDAP TMS S.A. also produces and
commercializes medical equipment for treatment of urinary tract
stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more
information on the Company, contact Magnolia Investor Relations at
(972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4
78 26 40 46 or see the Company's Web sites at
http://www.edap-tms.com/ and http://www.hifu-planet.com/. To sign
up for alerts please visit:
http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0 In
addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties.
These include statements regarding the Company's growth and
expansion plans. Such statements are based on management's current
expectations and are subject to a number of uncertainties and risks
that could cause actual results to differ materially from those
described in these forward-looking statements. Factors that may
cause such a difference include, but are not limited to, those
described in the Company's filings with the Securities and Exchange
Commission. Ablatherm-HIFU treatment is in clinical trials but not
yet FDA approved or marketed in the United States. CONTACT: EDAP
TMS S.A. Magnolia Investor Relations Blandine Confort Matt Kreps
+33 4 78 26 40 46 972 801 4900 DATASOURCE: EDAP TMS S.A. CONTACT:
Blandine Confort of EDAP TMS S.A., +33 4 78 26 40 46; or Matt Kreps
of Magnolia Investor Relations, +1-972-801-4900, for EDAP TMS S.A.
Web site: http://www.edap-tms.com/ http://www.hifu-planet.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024